HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.
OBJECTIVE
HIV elite controllers are a unique group of rare individuals who maintain undetectable viral loads in the absence of antiretroviral therapy. We studied immune responses in these individuals to inform vaccine development, with the goal of identifying the immune correlates of protection from HIV.


METHODS
We compared markers of cellular activation, HIV-specific immune responses and regulatory T (Treg) cell frequencies in four groups of individuals: HIV-negative healthy controls, elite controllers (HIV RNA level <75 copies/ml), individuals on HAART and individuals with HIV RNA level more than 10,000 copies/ml (noncontrollers).


RESULTS
Elite controllers possessed significantly lower levels of activated HIV-specific CD8 T cells and of recently divided HIV-specific CD4 T cells than noncontrollers, whereas these differences were not seen in the respective cytomegalovirus-specific T-cell populations. Elite controllers also mounted a stronger and broader cytokine and chemokine response following HIV-specific stimulation than individuals on HAART and noncontrollers. Finally, we found that HAART-suppressed individuals had elevated Treg cell frequencies, whereas elite controllers and noncontrollers maintained normal percentages of Treg cells.


CONCLUSIONS
Elite controllers maintain high levels of HIV-specific immune responses with low levels of HIV-specific T-cell activation and do not have elevated Treg cell levels. Based on these data an ideal HIV vaccine would induce strong HIV-specific immune responses whereas minimizing HIV-specific T-cell activation.
Owen
Rachel E
RE
Blood Systems Research Institute, San Francisco, CA 94118, USA.
Heitman
John W
JW
Hirschkorn
Dale F
DF
Lanteri
Marion C
MC
Biswas
Hope H
HH
Martin
Jeffrey N
JN
Krone
Melissa R
MR
Deeks
Steven G
SG
Norris
Philip J
PJ
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D019562:Viral Load
Clin Exp Immunol. 2009 Jan;155(1):44-52
19016807
J Immunol. 2005 Apr 1;174(7):4407-14
15778406
AIDS. 1994 Jun;8(6):757-62
8086133
Nat Immunol. 2005 Apr;6(4):345-52
15785760
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):577-80
18645514
J Immunol. 1993 Nov 1;151(9):5031-40
8409454
Clin Exp Immunol. 2007 Mar;147(3):533-9
17302904
J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):529-37
18193494
Blood. 2004 Nov 15;104(10):3249-56
15271794
J Infect Dis. 2008 Jan 1;197(1):126-33
18171295
Nat Rev Immunol. 2007 Mar;7(3):231-7
17318234
J Infect Dis. 2005 Mar 1;191(5):694-701
15688282
J Virol. 2008 Sep;82(17):8307-15
18579608
J Virol. 2001 Dec;75(24):11983-91
11711588
J Exp Med. 2006 Jul 10;203(7):1693-700
16818676
J Clin Invest. 2005 Jul;115(7):1953-62
16007258
J Immunol Methods. 2007 Jan 30;319(1-2):41-52
17173927
Clin Exp Immunol. 2008 Oct;154(1):80-6
18821942
AIDS. 2007 Jul 31;21(12):1525-34
17630546
Nat Immunol. 2003 Apr;4(4):330-6
12612578
Blood. 2009 Apr 23;113(17):3978-89
19109229
Immunity. 2007 Sep;27(3):406-16
17892849
Blood. 2006 Dec 1;108(12):3808-17
16902147
Nat Immunol. 2003 Apr;4(4):304-6
12660726
PLoS Med. 2008 May 6;5(5):e100
18462013
Clin Exp Immunol. 1991 Apr;84(1):109-15
1901776
AIDS. 1997 Jul 15;11(9):1111-8
9233457
Clin Exp Immunol. 1994 Mar;95(3):436-41
7907956
J Virol. 2009 Jan;83(1):329-35
18945778
Immunol Cell Biol. 2006 Dec;84(6):530-6
16956389
J Leukoc Biol. 2008 Feb;83(2):254-62
17982112
J Virol. 2005 Nov;79(22):14169-78
16254352
J Clin Invest. 1988 Dec;82(6):1908-14
2974045
AIDS Res Hum Retroviruses. 2006 Aug;22(8):757-62
16910831
Immunology. 2009 Sep;128(1 Suppl):e366-75
19016904
J Virol. 2009 Apr;83(8):3719-33
19176632
Immunology. 2007 Nov;122(3):445-53
17627771
J Virol. 2007 Dec;81(23):12748-57
17855517
J Neuroimmunol. 2007 Aug;188(1-2):117-27
17582512
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):83-92
9358102
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):373-81
15764953
J Exp Med. 2003 Sep 15;198(6):889-901
12975455
Clin Immunol. 2006 Aug;120(2):163-70
16765088
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
17428922
J Immunol. 2008 Jan 15;180(2):764-73
18178814
Blood. 2006 Jun 15;107(12):4781-9
16467198
Cytometry B Clin Cytom. 2007 Jan 15;72(1):22-33
17051525
J Immunol. 1995 Aug 1;155(3):1151-64
7636184
Clin Immunol. 2009 Mar;130(3):298-303
19008157
J Exp Med. 2006 Jul 10;203(7):1701-11
16818678
Nat Med. 2004 Aug;10(8):801-5
15286781
J Immunol. 2001 Aug 1;167(3):1245-53
11466340
AIDS. 2008 Oct 1;22(15):1937-41
18784457
Blood. 2008 Oct 1;112(7):2858-68
18544681
J Exp Med. 2000 Jul 17;192(2):303-10
10899917
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19851-6
19060209
Science. 1994 Jul 8;265(5169):248-52
8023143